CALC Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.46 and $7.20. With a market capitalization of about $9.27 million, CalciMedica, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.09). Key stats such as the average daily volume over the past year has been around 380.17 thousand shares, volume is running light vs its 52-week average. Headquartered in La Jolla, CA, CalciMedica, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO A. Rachel Leheny, the company employs approximately 14 people and listed since June 14, 2023. CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs.

CALC has shown sold momentum, gaining 3.7% over the past week and 74.45% over the past quarter, though year-to-date performance is down -15.02%. Short-term trend indicators are mixed aligned (SMA20 -14.98%, SMA50 -84.47%, SMA200 -81.64%). The stock’s 14-day RSI is 21.98 (weak momentum), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -92.33% below its high and over 9.5% above its low. Average 10-day trading volume of 127.57 thousand shares is below the 3-month average of 414.65 thousand, indicating normal recent market interest.

CalciMedica, Inc. trades at a P/E ratio of -304.83, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -1356.92 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.45, also below market averages.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

CalciMedica, Inc. generated EPS of -$1.61 over the past year. Five-year average earnings growth is 47.54%. Wall Street analysts project EPS growth of -14.33% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $20.00. The high target offers 3289.83% upside. The low target suggests 3289.83% downside. The mean target is $20.00. This offers 3289.83% upside. CalciMedica, Inc. earnings surprise history is a mixed track record. The quarter that ended March 03, 2026, missed forecasts by -41.82%. The prior quarter beat by 1162.51%. Over the last six quarters, Apple has recorded several small beats. These include -18.03% in November 13, 2024.

CalciMedica, Inc. has 13.97 million shares outstanding. The public float is 5.42 million shares, elevated short interest at 0.38% of float. This equals 35.59 thousand shares. The short ratio is 0.36 days. Institutional investors hold 70.21% of the float. Insiders own 16.76%. HOVDE ERIC D holds 1.43 million shares, WILSON ROBERT N has 422.03 thousand shares and Roberts Eric W has 84.15 thousand shares.